In this study, it was revealed that iron chelator SIH has no potential to blunt anticancer efficacy of anthracyclines and it is able to afford significant cardioprotection against chronic anthracycline cardiotoxicity in rabbits. However, it was revealed that it shares the same paradox dose-dependency with other aroylhydrazones.